<<

. 2
( 2 .)




554 13, 8, 2005
eOCaAieaeEau
i?e iee?ie?enoaeee?aneii ainiaeaiee. Ieianee
ieacuaaao oae?a iiin?aaiaaiiia aeeyiea ia aeoea-
iinou oaeoi?a aeoeaaoee o?iiaioeoia, oaeoi?a iae?i-
ca iiooiee–?, eiaeae?iaaiea oinoiaeynoa?acu IV,
iaoaeeii?ioaeiacu, oa?iaioia, ea?a?ueo iaio ec
aeaaainoao?ueo ?ieae a iaoaieciao ino?iai ainiaea-
iey, naycaiiuo n aeoeaaoeae iaeo?ioeeia e oaaioeoia
[3]. A nayce n ?ai eniieuciaaiea ieianoeeaa i?e ii-
aaa?e?aneii a?o?eoa yaeyaony iaoiaaiaoe?anee iain-
iiaaiiui.
I?aanoaaey?ony iniaaiii aa?iuie aunieay yo-
oaeoeaiinou e oi?ioay ia?aiineiinou Ieianeea
i?e iaee?ee niioonoao?uae iaoieiaee ?acee?iuo nen-
?en. 1. Oeo?oaiea nooi?iiai i?ioeey
oai i?aaiecia, iineieueo ni?aoaiea iiaaa?u n ii?a?a-
i?e eoie?iaaiee iiaaa?e?aneiai a?o?eoa
ieai ?EO, ia?aie, ii?ae, a?oa?eaeuiie aeia?oaicee,
aue aeceo, iu ia ioiaoeee eaeiai–eeai nouanoaaiiiai NA 2 oeia, ii?ii n?eoaou iaeeaaoiuie. Oaeia ni?aoaiea
aae?aiey a aeiaieea AA. I?eiaiaiea nooi?iiai iiie- nouanoaaiii iiauoaao noaiaiu ?enea o aieuiuo iiaaa-
oi?e?iaaiey AA (NIAA) iieacaei, ?oi o aieuiuo aac AA, ?ie aneaanoaea io?eoaoaeuiiai aeeyiey IIAI ia ninoi-
iieo?a?ueo Ieianee, eciaiaiea n?aaieo cia?aiee yiea neecenoie ?acee?iuo ioaaeia ?EO, ?acaeoea na?u-
NAA/AAA auee iaainoiaa?iuie e ninoaaeee aciuo aaiaoioiene?aneeo e iao?ioiene?aneeo ?aaeoee, a
2–5 ii ?o.no., iacia?eoaeuii iaiyeenu iieacaoaee aa- oae?a ii?a?aiea na?aa?ii–ninoaenoie nenoaiu, ?oi ni-
?eaaaeuiinoe (EA), ainoiaa?ii oeo?oaeny nooi?iue caaao ii?aaaeaiiua o?oaiinoe i?e iiaai?a aaaeaaoiie
i?ioeeu AA. O o?aoe aieuiuo ioia?aeinu iiauoaiiia i?ioeaiainiaeeoaeuiie oa?aiee.
AA, iaeneiaeuii ai 200/130 ii ?o.no., ana yoe iaoeaiou E?iia oiai, iaoa enneaaiaaiea iieacaei aunieo?
iieo?aee aeiioaiceaio? oa?aie? (eiaeaeoi?u AIO e yooaeoeaiinou Ieianeea aey eoie?iaaiey ino?iai e
?–aeieaoi?u). I?e aaooiaaaeuiii i?eaia i?aia?aoa o o?iie?aneiai iiaaa?e?aneiai ainiaeaiey, a oae?a ioii-
oaeeo aieuiuo iieacaoaee NIAA ia eciaieeenu, a ii neoaeuio? aaciianiinou i?eiaiaiey aaoo– e o?aoia-
iaeioi?ui cia?aieyi aa?a oiaiuoeeenu. Ainoiaa?ii aaeuiuo eo?nia o aieuiuo iiaaa?ie.
nieceeinu NAA (ia 16 ii ?o.no.) e AAA (ia 8 ii ?o.no.),
aEUA?UU?
ii?iaeeciaaeny nooi?iue ?eoi (?en. 1). Aicii?ii, ?oi
1. cOOIO‚ C.A., A?OIO‚ C.E. eIIEA E„IOOUEI E IA?AIEA OO„?? – IU?IO
yoi ?anoe?ii naycaii ni cia?eoaeuiui oiaiuoaieai
O·OOIO‚IIOA U?A·O‚IEA UIU??AIE? U?UO‚O„O E EEAIAIIO„O O?O„IOA ·OI?I??.
aieaaiai neia?iia.
cU?IO–O?IUE?AOI? ?A‚IUOIO„E? 2004, 1, 5–7
Ia?aiineiinou oa?aiee Ieianeeii a oaeii auea oi- 2. Vane J.R., Booting R.M. Mechanism of action of anti–inflammatory drags. Scand. J.
?ioae. Ia?aeaoaeuiua ?aaeoee, ioia?aiiua ia oiia oa- Rheumatol. 1996; 102: 9.
?aiee, iio?aaiaaaoea ioiaiu i?aia?aoa, ca?aaeno?e?i- 3. cOOIO‚ O.a. O?EIAIAIEA IAOUA?OEI?? O?OUE‚O‚OOOIEUAI?I?? O?AO?UO‚ ‚
IAE?EIA ‚ I?IA 21 ‚AI. eaU 2003, UOI 11, 7 OU?. 7–9.
aaiu o 5 aieuiuo (o 4 ec ieo – i?e cia?eoaeuiii iiei?e-
4. Schumacher H.R., Boice J.A., Daikh D.I., et al. Randomised double blind trial of etori-
oaeuiii yooaeoa a ioiioaiee nonoaaiiai neia?iia). O 2
coxib and indomethacin in treatment of acute gouty arthritis. BMJ 2002; J 22; 324
aieuiuo ioia?aeny iiauai a?oa?eaeuiiai aaaeaiey. I?e (7352): 1488–1492.
yoii iaei naiinoiyoaeuii ioiaiee iieo?aaio? ?aiaa ae- 5. A?OIO‚ C.E., uIUIEI a.A., cOOIO‚ C.A. e?EIAIAIEA IEIAOEI O?E OO„?E?A-
iioaiceaio? oa?aie?. O iaiiai aieuiiai ?acaeeny ioae OIOI ?U?EUA. iA? ??E‚ 2003, 5 UOI 75 OU?. 60–64
6. Wallace SL, Robinson H, Masi AT, et al: Preliminary criteria for the classification of the
eeoa e eiau?ae, ia nii?iai?aa?ueeny a?oaeie neiioi-
acute arthritis of primary gout. Arthritis Rheum 1977; 20: 895–900
iaie eee eciaiaieai eiio?iee?oaiuo iaie iieacaoa-
7. Bennett WM, Debroe MA. Analgesic nephropathy – a preventable renal disease. N Engl
eae. Iaei aieuiie auaue ec enneaaiaaiey a nayce n ?ac- J Med 1989; 320: 1269–1271
aeoeai e?aieaieou ia 5–e aaiu i?eaia i?aia?aoa. Eeou 8. Ya T.F., Berger L. Impaired renal function in gout. Its association with hypertensive
o iaiiai aieuiiai ioia?aeinu iaino?aiea nonoaaiiai vascular disease and intrinsic renal disease. Am. J. med. 1982; 72: 95–100.
9. Nickeleit V., Mihatsch M. J. Uric acid nephropathy and end–stage renal disease:
neia?iia: i?e ouaoaeuiii ?anni?ina auynieeinu, ?oi
Review of non–disease. Nephrol. Dial. Transplant. 1997; 12: 1832–1838.
aieuiie naiinoiyoaeuii auiieiee ianna? noiiu. I?aia-
?ao aue ioiaiai a nayce n iaaaoeaiui ioiioaieai aieu-
iiai. O iaiiai iaoeaioa aicieeee aiee a yieaano?ee, ei-
oi?ua ioia?aeenu ?aiaa a aieaa au?a?aiiie oi?ia ia
i?eai e?auo IIAI, iaiaei ioiaiyou i?aia?ao ec–ca au-
?a?aiiie yooaeoeaiinoe aieuiie ioeacaeny, aiee auee
eoie?iaaiu i?eaiii iiai?aciea.

Caee??aiea

Ieianee ii?ao n?eoaouny i?aia?aoii auai?a,
i?eiaiyaiui aey eoie?iaaiey iiaaa?e?aneiai
a?o?eoa, iineieueo iieacai aai o?iieci e iiaaaeaie?
aeoeaiinoe OIA–2 ia iaeo?ioeeao e iae?ioaaao,
i?aanoaaey?ueo niaie aaaouea eeaoi?iua iiioeyoee

<<

. 2
( 2 .)